Start Your Free Trial

Providing evolved investors and entrepreneurs with the information needed to build businesses that advance people, planet and profit. Get free access for 7 days - no credit card required.

Start Your Free Trial

Join Karma Today

Gain access to our entire library of content for a limited time - no credit card required.

Poseida CEO Eric Ostertag on Standing Out in Crowded Biotech Field

Sound Businesses: Profiles of companies and business models we are keeping an eye on.


It’s been an interesting year for Poseida Therapeutics, the human therapeutics company that spun out of Transposagen Biopharmaceuticals in 2015. Poseida in January filed for an IPO, only to have it delayed due to the government shutdown. Then, talks with private investors advanced and Poseida nixed its IPO plans in favor of a funding round.


On April 22, the San Diego-based company announced a $142 million Series C funding round led by Swiss pharmaceutical giant Novartis, which invested $75 million. Poseida’s main focus is CAR-T cell therapy for patients with multiple myeloma, which affects about 300,000 Americans a year.

Join Karma Today

Gain access to our entire library of content for a limited time - no credit card required.

THIS ARTICLE IS EXCLUSIVE TO

Karma Members

arrow-right-light

Industry News

Every day, we break down the most significant private market headlines and deals.

arrow-right-light

Company & Investor Profiles

Conversations with investors and entrepreneurs we are keeping an eye on.

arrow-right-light

Perspectives from Thought Leaders

Opinions from our network on the risks and opportunities seen in key business sectors.

What is Karma Network?

Karma is a content platform for opinion and analysis from today’s leading investors, entrepreneurs and analysts on the risks and opportunities surrounding industry-shaping businesses and ideas.